[
  {
    "ts": null,
    "headline": "Investor seizes Novo Nordisk board in weight-loss drug battle",
    "summary": "STORY: Novo Nordisk’s top shareholder moved to take control of the company’s board Tuesday in an effort to revive sales of its blockbuster weight-loss drug Wegovy in the key U.S. market.It comes as the board chair and six other board members quit.The non-profit Novo Nordisk Foundation, which combines business ownership with philanthropy, said it would propose former CEO Lars Rebien Sorensen as chair to lead the Danish drugmaker's board for the next two or three years.The clash brings fresh upheaval to a company that soared to become Europe's most valuable company last year on the huge success of Wegovy.This year, the stock has plunged more than 40% as rival Eli Lilly grabbed market share.The foundation criticized the outgoing board for being too slow to recognize shifts in the key U.S. market and too cautious on management change.However, the foundation is still backing CEO Mike Doustdar who took over in August and has ushered in widespread job cuts and a drive to refocus the company on its key markets.One portfolio manager told Reuters he did not favor the changes, saying quote, \"I don't really get it – why does the old CEO have to be the new Chairman? Don't like it.\"U.S.-listed shares of Novo Nordisk fell 1.7% Tuesday",
    "url": "https://finnhub.io/api/news?id=c1eadabf7658447e20c5f6d3e115affe8f8902289bc7876022d845e1adb4e3a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761083406,
      "headline": "Investor seizes Novo Nordisk board in weight-loss drug battle",
      "id": 137187692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk’s top shareholder moved to take control of the company’s board Tuesday in an effort to revive sales of its blockbuster weight-loss drug Wegovy in the key U.S. market.It comes as the board chair and six other board members quit.The non-profit Novo Nordisk Foundation, which combines business ownership with philanthropy, said it would propose former CEO Lars Rebien Sorensen as chair to lead the Danish drugmaker's board for the next two or three years.The clash brings fresh upheaval to a company that soared to become Europe's most valuable company last year on the huge success of Wegovy.This year, the stock has plunged more than 40% as rival Eli Lilly grabbed market share.The foundation criticized the outgoing board for being too slow to recognize shifts in the key U.S. market and too cautious on management change.However, the foundation is still backing CEO Mike Doustdar who took over in August and has ushered in widespread job cuts and a drive to refocus the company on its key markets.One portfolio manager told Reuters he did not favor the changes, saying quote, \"I don't really get it – why does the old CEO have to be the new Chairman? Don't like it.\"U.S.-listed shares of Novo Nordisk fell 1.7% Tuesday",
      "url": "https://finnhub.io/api/news?id=c1eadabf7658447e20c5f6d3e115affe8f8902289bc7876022d845e1adb4e3a9"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Stock Moves -1.16%: What You Should Know",
    "summary": "Eli Lilly (LLY) reached $799.57 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=e3f34f622a354b99465fd05d80da8724fdb1abcb804735574f82df7008b61052",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761083104,
      "headline": "Eli Lilly (LLY) Stock Moves -1.16%: What You Should Know",
      "id": 137187693,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (LLY) reached $799.57 at the closing of the latest trading day, reflecting a -1.16% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=e3f34f622a354b99465fd05d80da8724fdb1abcb804735574f82df7008b61052"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk’s Entire Board Is Stepping Down in a Surprise Move. Here’s Why.",
    "summary": "The board turmoil represents a breakdown in relations between the company and its controlling shareholder.",
    "url": "https://finnhub.io/api/news?id=b326792bd55b9d7d5c1d516ff058dd8afe37990d5d06622a79d98147e569a18f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761069900,
      "headline": "Novo Nordisk’s Entire Board Is Stepping Down in a Surprise Move. Here’s Why.",
      "id": 137181808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The board turmoil represents a breakdown in relations between the company and its controlling shareholder.",
      "url": "https://finnhub.io/api/news?id=b326792bd55b9d7d5c1d516ff058dd8afe37990d5d06622a79d98147e569a18f"
    }
  },
  {
    "ts": null,
    "headline": "United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt",
    "summary": "The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized diabetes solutions. Rapid acting insulin, essential for managing post-meal blood sugar surges, is favored for its quick efficacy. Innovations such as insulin pens and pumps, coupled with favorable he",
    "url": "https://finnhub.io/api/news?id=25b13d86b2cb421774c35a0a03bdf14ff9003d7ce01473fab5635abdf4118420",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761053400,
      "headline": "United States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, Wockhardt",
      "id": 137177887,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The United States Rapid Acting Insulin Market is poised for significant growth, increasing from US$ 2.32 Billion in 2024 to US$ 3.40 Billion by 2033, with a CAGR of 4.33%. Key growth drivers include the rising diabetes prevalence, advancements in insulin delivery systems, and a surge in personalized diabetes solutions. Rapid acting insulin, essential for managing post-meal blood sugar surges, is favored for its quick efficacy. Innovations such as insulin pens and pumps, coupled with favorable he",
      "url": "https://finnhub.io/api/news?id=25b13d86b2cb421774c35a0a03bdf14ff9003d7ce01473fab5635abdf4118420"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs Novo Nordisk: One To Walk Away From And One To Run Away From",
    "summary": "Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation risks.",
    "url": "https://finnhub.io/api/news?id=fa0cd5296620db9b11e65fcdee2fe238e1f6f672ba78209ff5e32b6c9a0480cc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761048021,
      "headline": "Eli Lilly Vs Novo Nordisk: One To Walk Away From And One To Run Away From",
      "id": 137179515,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2172492554/image_2172492554.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover how potential U.S. price cuts on obesity drugs could impact LLY and NVO revenues, stock sentiment, and valuation risks.",
      "url": "https://finnhub.io/api/news?id=fa0cd5296620db9b11e65fcdee2fe238e1f6f672ba78209ff5e32b6c9a0480cc"
    }
  },
  {
    "ts": null,
    "headline": "Did Eli Lilly Just Say \"Checkmate\" to Novo Nordisk?",
    "summary": "The tides continue to change in Eli Lilly's favor in the GLP-1 space.",
    "url": "https://finnhub.io/api/news?id=872ead7168f9e719e922fbd11cfdf4a3515a1172a85e671971752a8aadbcacf2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761037200,
      "headline": "Did Eli Lilly Just Say \"Checkmate\" to Novo Nordisk?",
      "id": 137176521,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The tides continue to change in Eli Lilly's favor in the GLP-1 space.",
      "url": "https://finnhub.io/api/news?id=872ead7168f9e719e922fbd11cfdf4a3515a1172a85e671971752a8aadbcacf2"
    }
  },
  {
    "ts": null,
    "headline": "3 takeaways for investors tracking executive insider trades",
    "summary": "Insider company trading doesn't always follow the same script. Here's how to track and make sense of in-house trades",
    "url": "https://finnhub.io/api/news?id=ac789a4ed93fe11b48105e5ee38ae1744861c6c6a4fe872dbe0f91c0c89afc44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761037200,
      "headline": "3 takeaways for investors tracking executive insider trades",
      "id": 137173835,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insider company trading doesn't always follow the same script. Here's how to track and make sense of in-house trades",
      "url": "https://finnhub.io/api/news?id=ac789a4ed93fe11b48105e5ee38ae1744861c6c6a4fe872dbe0f91c0c89afc44"
    }
  }
]